[go: up one dir, main page]

WO2007011647A3 - Inhibiteurs de la kinesine mitotique - Google Patents

Inhibiteurs de la kinesine mitotique Download PDF

Info

Publication number
WO2007011647A3
WO2007011647A3 PCT/US2006/027217 US2006027217W WO2007011647A3 WO 2007011647 A3 WO2007011647 A3 WO 2007011647A3 US 2006027217 W US2006027217 W US 2006027217W WO 2007011647 A3 WO2007011647 A3 WO 2007011647A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
mitotic kinesin
kinesin ksp
ksp
mitotic
Prior art date
Application number
PCT/US2006/027217
Other languages
English (en)
Other versions
WO2007011647A2 (fr
Inventor
Anthony B Pinkerton
Robert L David
Original Assignee
Kalypsys Inc
Anthony B Pinkerton
Robert L David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc, Anthony B Pinkerton, Robert L David filed Critical Kalypsys Inc
Publication of WO2007011647A2 publication Critical patent/WO2007011647A2/fr
Publication of WO2007011647A3 publication Critical patent/WO2007011647A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à des composés et à des procédés qui peuvent servir d'inhibiteurs de la kinésine KSP, pour le traitement ou la prévention des maladies prolifératives cellulaires.
PCT/US2006/027217 2005-07-15 2006-07-13 Inhibiteurs de la kinesine mitotique WO2007011647A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69952105P 2005-07-15 2005-07-15
US60/699,521 2005-07-15
US76161306P 2006-01-24 2006-01-24
US60/761,613 2006-01-24

Publications (2)

Publication Number Publication Date
WO2007011647A2 WO2007011647A2 (fr) 2007-01-25
WO2007011647A3 true WO2007011647A3 (fr) 2007-05-18

Family

ID=37622033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/027217 WO2007011647A2 (fr) 2005-07-15 2006-07-13 Inhibiteurs de la kinesine mitotique

Country Status (1)

Country Link
WO (1) WO2007011647A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003079973A2 (fr) * 2002-03-08 2003-10-02 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
WO2006002236A1 (fr) * 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. Derives de n-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dymethylpropyl) benzamide et composes associes comme inhibiteurs de la proteine kinesine fuseau (ksp) pour le traitement du cancer
WO2006031607A2 (fr) * 2004-09-13 2006-03-23 Merck & Co., Inc. Methode de traitement du cancer
WO2006068933A2 (fr) * 2004-12-21 2006-06-29 Merck & Co., Inc. Inhibiteurs de la kinesine mitotique
WO2006098961A2 (fr) * 2005-03-09 2006-09-21 Schering Corporation Composes servant a inhiber l'activite de la kinesine ksp
WO2006098962A1 (fr) * 2005-03-09 2006-09-21 Schering Corporation Composes inhibant l'activite de la kinesine ksp

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003079973A2 (fr) * 2002-03-08 2003-10-02 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
WO2006002236A1 (fr) * 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. Derives de n-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dymethylpropyl) benzamide et composes associes comme inhibiteurs de la proteine kinesine fuseau (ksp) pour le traitement du cancer
WO2006031607A2 (fr) * 2004-09-13 2006-03-23 Merck & Co., Inc. Methode de traitement du cancer
WO2006068933A2 (fr) * 2004-12-21 2006-06-29 Merck & Co., Inc. Inhibiteurs de la kinesine mitotique
WO2006098961A2 (fr) * 2005-03-09 2006-09-21 Schering Corporation Composes servant a inhiber l'activite de la kinesine ksp
WO2006098962A1 (fr) * 2005-03-09 2006-09-21 Schering Corporation Composes inhibant l'activite de la kinesine ksp

Also Published As

Publication number Publication date
WO2007011647A2 (fr) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2007011759A3 (fr) Inhibiteurs de la kinesine mitotique
WO2007011760A3 (fr) Inhibiteurs de la kinesine mitotique
WO2008011560A3 (fr) Inhibiteurs de la rho kinase à base de benzothiophène
WO2006078287A3 (fr) Inhibiteurs de pde4b
WO2008079988A3 (fr) Quinazolines destinés à l'inhibition de pdk1
WO2006078574A3 (fr) Inhibiteurs mitotiques de la kinesine
WO2005117867A3 (fr) Heterocycles monocycliques commes inhibiteurs de kinases
WO2005017190A3 (fr) Inhibiteurs de kinesine mitotique
WO2007025090A3 (fr) Inhibiteurs de kinase mapk/erk
WO2006023651A3 (fr) Traitement prolonge de la sclerose en plaques
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2005018547A3 (fr) Inhibiteurs de kinesine mitotique
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
WO2006119295A3 (fr) Compositions et methodes de traitement de maladies neurodegeneratives
WO2008149353A3 (fr) Composés activant la télomérase et leurs procédés d'utilisation
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
WO2007121125A3 (fr) Composés organiques et leurs utilisations
WO2006086358A3 (fr) Inhibiteurs de kinesines mitotiques
WO2006078598A3 (fr) Inhibiteurs de la kinesine mitotique
WO2006081516A3 (fr) Utilisation de baff pour traiter des pathologies induites par th2
WO2006101761A3 (fr) Inhibiteurs de kinesine mitotique
TNSN08496A1 (en) Aminothiazoles and their uses
WO2006068933A3 (fr) Inhibiteurs de la kinesine mitotique
WO2005117939A3 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
WO2005060654A3 (fr) Inhibiteurs de kinesines mitotiques

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06787160

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06787160

Country of ref document: EP

Kind code of ref document: A2